106 related articles for article (PubMed ID: 20979308)
1. [Methodology of gene therapy: adverse events and further technological developments].
Hamada H
Nihon Rinsho; 2010 Aug; 68 Suppl 8():601-6. PubMed ID: 20979308
[No Abstract] [Full Text] [Related]
2. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
3. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
4. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
5. Gene therapy. RAC's advice: proceed with caution.
Kaiser J
Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
[No Abstract] [Full Text] [Related]
6. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
7. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
8. Success and setback: another adverse event.
Verma IM
Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
[No Abstract] [Full Text] [Related]
9. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
10. US panel advises resumption of gene trials.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1068-9. PubMed ID: 12410240
[No Abstract] [Full Text] [Related]
11. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
12. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
14. Regulators split on gene therapy as patient shows signs of cancer.
Check E
Nature; 2002 Oct; 419(6907):545-6. PubMed ID: 12374936
[No Abstract] [Full Text] [Related]
15. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
16. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
17. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
18. Risks and benefits of gene therapy.
Noguchi P
N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
[No Abstract] [Full Text] [Related]
19. Bubble babies and bathwater.
Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
[No Abstract] [Full Text] [Related]
20. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
[Next] [New Search]
